All updated as on -
By 2030, the market for systemic scleroderma treatments is anticipated to reach USD 2259.0 million, growing at a CAGR of 5.5% from 2023 to 2030. An autoimmune condition called systemic scleroderma causes the skin and internal organs to thicken and stiffen. One of the main factors influencing the development of systemic scleroderma treatments and the demand for them is the exponential expansion in the number of government efforts and services available to promote understanding about the illness and therapeutic choices.
The exceedingly rare and chronic disease sclerosis, also known as sclerosis, is characterised by an excessive synthesis of collagen in the body's tissues. Skin is primarily affected by scleroderma. It can affect a number of vital internal organs, including the kidney, lungs, heart, and others, and is not just limited to the skin. The medical term for the condition when tissue thickening may be seen in the internal organs as well as the skin is systemic scleroderma. It could be challenging to move the area affected by the condition due to the tightness and hardness of skin patches brought on by systemic scleroderma. Depending on how serious the systemic scleroderma disease is, the number of patches and their size may vary. Raynaud's syndrome, a disorder that causes discomfort and numbness in the fingers or toes in response to cold temperatures, is one of the early signs of systemic scleroderma. Systemic scleroderma may impact the gastrointestinal tract, which could lead to heartburn, diarrhoea, constipation, cramps, and a diminished capacity for the body to adequately absorb nutrients from the food it eats into its cells. Systemic scleroderma has the potential to become lethal if it is not treated in a timely manner. To treat systemic scleroderma, pharmaceutical and biotechnology companies are developing new potential medicines. One reason driving the market for systemic scleroderma treatment is this. For instance, in November 2020, the European Commission gave Boehringer Ingelheim permission to use nintedanib in people with interstitial lung disease associated with systemic sclerosis. Interstitial lung disease linked to systemic sclerosis is treated with nintedanib. Abbvie's ALPN-101, a medication being developed to treat systemic lupus erythematosus, has successfully completed its Phase 3 research. Novartis also completed the Phase 2 trial of nilotinib for the treatment of systemic sclerosis effectively. This accomplishment was made possible since Novartis successfully finished and passed the trial, which is anticipated to increase the market for systemic scleroderma treatments.
The market for treating systemic scleroderma is divided into immunosuppressants, calcium channel blockers, proton pump inhibitors, phosphodiesterase 5 inhibitors, endothelin receptor antagonists, prostacyclin analogues, and others based on the drug type. Endothelin receptor antagonists had the largest market share (20%) and the highest market value (304.02 million) in 2021. Endothelin receptors, especially type A receptors, can be effectively blocked by medications from the class of medications known as endothelin receptor antagonists (ERA). Vasodilation is brought on by this, and it may lower blood pressure and enhance blood flow to organs like the kidney, liver, and brain. These possibilities include ambrisentan, bosentan, sitaxsentan, and macitentant. These drugs are used to treat scleroderma and pulmonary arterial hypertension (PAH). Its effects on scleroderma cause it to be overused, which boosts the market.
Report Coverage
Global Systemic Scleroderma Treatment research report categorizes the market for global based on various segments and regions, forecasts revenue growth, and analyzes trends in each submarket. Global Systemic Scleroderma Treatment report analyses the key growth drivers, opportunities, and challenges influencing the global market. Recent market developments and Systemic Scleroderma Treatment competitive strategies such as expansion, product launch and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key Systemic Scleroderma Treatment market players and analyses their core competencies in each global market sub-segments.
Key Points Covered in the Report
Competitive Environment:
The research provides an accurate study of the major organisations and companies operating in the global Systemic Scleroderma Treatment market, along with a comparative evaluation based on their product portfolios, corporate summaries, geographic reach, business plans, Systemic Scleroderma Treatment market shares in specific segments, and SWOT analyses. A detailed analysis of the firms' recent news and developments, such as product development, inventions, joint ventures, partnerships, mergers and acquisitions, strategic alliances, and other activities, is also included in the study. This makes it possible to assess the level of market competition as a whole.
List of Major Market Participants
Bristol-Myers Squibb Company, Boehringer Ingelheim International GmbH, Allergan, Actelion Pharmaceuticals Ltd, F. Hoffmann-La Roche Ltd, GlaxoSmithKline plc., Biogen, Novartis AG, Teva Pharmaceutical Industries Ltd., AstraZeneca, Celgene Corporation, Ono pharmaceutical co. Ltd, Aspen Holdings, Corbus Pharmaceuticals, Pfizer Inc., Eli Lilly and Company, Bayer AG, Argentis Pharmaceuticals, LLC., Amgen Inc., Sanofi
Primary Target Market
Market Segment:
This study forecasts global, regional, and country revenue from 2019 to 2030. Spherical Insights has segmented the global Systemic Scleroderma Treatment market based on the below-mentioned segments:
Global Systemic Scleroderma Treatment Market, By Drug Class Type
Global Systemic Scleroderma Treatment market, By Disease Type
Global Systemic Scleroderma Treatment Market, By End User
Global Systemic Scleroderma Treatment market, Regional Analysis
The exceedingly rare and chronic disease sclerosis, also known as sclerosis, is characterised by an excessive synthesis of collagen in the body's tissues. Skin is primarily affected by scleroderma. It can affect a number of vital internal organs, including the kidney, lungs, heart, and others, and is not just limited to the skin. The medical term for the condition when tissue thickening may be seen in the internal organs as well as the skin is systemic scleroderma. It could be challenging to move the area affected by the condition due to the tightness and hardness of skin patches brought on by systemic scleroderma. Depending on how serious the systemic scleroderma disease is, the number of patches and their size may vary. Raynaud's syndrome, a disorder that causes discomfort and numbness in the fingers or toes in response to cold temperatures, is one of the early signs of systemic scleroderma. Systemic scleroderma may impact the gastrointestinal tract, which could lead to heartburn, diarrhoea, constipation, cramps, and a diminished capacity for the body to adequately absorb nutrients from the food it eats into its cells. Systemic scleroderma has the potential to become lethal if it is not treated in a timely manner. To treat systemic scleroderma, pharmaceutical and biotechnology companies are developing new potential medicines. One reason driving the market for systemic scleroderma treatment is this. For instance, in November 2020, the European Commission gave Boehringer Ingelheim permission to use nintedanib in people with interstitial lung disease associated with systemic sclerosis. Interstitial lung disease linked to systemic sclerosis is treated with nintedanib. Abbvie's ALPN-101, a medication being developed to treat systemic lupus erythematosus, has successfully completed its Phase 3 research. Novartis also completed the Phase 2 trial of nilotinib for the treatment of systemic sclerosis effectively. This accomplishment was made possible since Novartis successfully finished and passed the trial, which is anticipated to increase the market for systemic scleroderma treatments.
The market for treating systemic scleroderma is divided into immunosuppressants, calcium channel blockers, proton pump inhibitors, phosphodiesterase 5 inhibitors, endothelin receptor antagonists, prostacyclin analogues, and others based on the drug type. Endothelin receptor antagonists had the largest market share (20%) and the highest market value (304.02 million) in 2021. Endothelin receptors, especially type A receptors, can be effectively blocked by medications from the class of medications known as endothelin receptor antagonists (ERA). Vasodilation is brought on by this, and it may lower blood pressure and enhance blood flow to organs like the kidney, liver, and brain. These possibilities include ambrisentan, bosentan, sitaxsentan, and macitentant. These drugs are used to treat scleroderma and pulmonary arterial hypertension (PAH). Its effects on scleroderma cause it to be overused, which boosts the market.
Report Coverage
Global Systemic Scleroderma Treatment research report categorizes the market for global based on various segments and regions, forecasts revenue growth, and analyzes trends in each submarket. Global Systemic Scleroderma Treatment report analyses the key growth drivers, opportunities, and challenges influencing the global market. Recent market developments and Systemic Scleroderma Treatment competitive strategies such as expansion, product launch and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key Systemic Scleroderma Treatment market players and analyses their core competencies in each global market sub-segments.
| REPORT ATTRIBUTES | DETAILS |
|---|---|
| Study Period | 2017-2030 |
| Base Year | 2020 |
| Forecast Period | 2022-2030 |
| Historical Period | 2017-2019 |
| Unit | Value (USD Billion) |
| Key Companies Profiled | Bristol-Myers Squibb Company, Boehringer Ingelheim International GmbH, Allergan, Actelion Pharmaceuticals Ltd, F. Hoffmann-La Roche Ltd, GlaxoSmithKline plc., Biogen, Novartis AG, Teva Pharmaceutical Industries Ltd., AstraZeneca, Celgene Corporation, Ono pharmaceutical co. Ltd, Aspen Holdings, Corbus Pharmaceuticals, Pfizer Inc., Eli Lilly and Company, Bayer AG, Argentis Pharmaceuticals, LLC., Amgen Inc., Sanofi |
| Segments Covered | • By Product |
| Customization Scope | Free report customization (equivalent to up to 3 analyst working days) with purchase. Addition or alteration to country, regional & segment scope |
Key Points Covered in the Report
- Market Revenue of Systemic Scleroderma Treatment Market from 2021 to 2030.
- Market Forecast for Systemic Scleroderma Treatment Market from 2021 to 2030.
- Regional Market Share and Revenue from 2021 to 2030.
- Country Market share within region from 2021 to 2030.
- Key Type and Application Revenue and forecast.
- Company Market Share Analysis, Systemic Scleroderma Treatment competitive scenario, ranking, and detailed company
profiles. - Market driver, restraints, and detailed COVID-19 impact on Systemic Scleroderma Treatment
Market
Competitive Environment:
The research provides an accurate study of the major organisations and companies operating in the global Systemic Scleroderma Treatment market, along with a comparative evaluation based on their product portfolios, corporate summaries, geographic reach, business plans, Systemic Scleroderma Treatment market shares in specific segments, and SWOT analyses. A detailed analysis of the firms' recent news and developments, such as product development, inventions, joint ventures, partnerships, mergers and acquisitions, strategic alliances, and other activities, is also included in the study. This makes it possible to assess the level of market competition as a whole.
List of Major Market Participants
Bristol-Myers Squibb Company, Boehringer Ingelheim International GmbH, Allergan, Actelion Pharmaceuticals Ltd, F. Hoffmann-La Roche Ltd, GlaxoSmithKline plc., Biogen, Novartis AG, Teva Pharmaceutical Industries Ltd., AstraZeneca, Celgene Corporation, Ono pharmaceutical co. Ltd, Aspen Holdings, Corbus Pharmaceuticals, Pfizer Inc., Eli Lilly and Company, Bayer AG, Argentis Pharmaceuticals, LLC., Amgen Inc., Sanofi
Primary Target Market
- Market Players of Systemic Scleroderma Treatment
- Investors
- End-users
- Government Authorities
- Consulting And Research Firm
- Venture capitalists
- Third-party knowledge providers
- Value-Added Resellers (VARs)
Market Segment:
This study forecasts global, regional, and country revenue from 2019 to 2030. Spherical Insights has segmented the global Systemic Scleroderma Treatment market based on the below-mentioned segments:
Global Systemic Scleroderma Treatment Market, By Drug Class Type
- Immunosuppressants
- Calcium channel blockers
- Proton pump inhibitors
- Glucocorticoids
- Alkylating agents
- Interleukin inhibitors
- Others
Global Systemic Scleroderma Treatment market, By Disease Type
- Limited systemic sclerosis
- Generalized systemic sclerosis
- Systemic sclerosis sine scleroderma
Global Systemic Scleroderma Treatment Market, By End User
- Oral
- Parenteral
Global Systemic Scleroderma Treatment market, Regional Analysis
- Europe: Germany, Uk, France, Italy, Spain, Russia, Rest of Europe
- The Asia Pacific: China,Japan,India,South Korea,Australia,Rest of Asia Pacific
- South America: Brazil, Argentina, Rest of South America
- Middle East & Africa: UAE, Saudi Arabia, Qatar, South Africa, Rest of Middle East & Africa
About This Research
You will get in-depth and extensive systemic scleroderma treatment market market research and competitor analysis for your business to help you develop more profound insights into the systemic scleroderma treatment market Market.
Through INFINITIVE Data Expert is a professional Market Research services, I will identify the systemic scleroderma treatment market market size, demand & opportunities, growth rate, and target audience with a comprehensive analysis of your competitors.